Full Year 2021 Results Press Release

ROVI reports operating revenue growth of 54% and net profit growth of 151%


ROVI REPORTS OPERATING REVENUE GROWTH OF 54% AND NET PROFIT GROWTH OF 151%

  • Operating revenue increased by 54% to 648.7 million euros driven by (i) the strength of the contract manufacturing organization (“CMO”) business, which grew by 189%, and (ii) the specialty pharmaceutical business, where sales rose 17%.
  • Sales of the heparin franchise (Low Molecular Weight Heparins (LMWH) and other heparins) increased by 16% to 242.0 million euros. Sales of the enoxaparin biosimilar increased 22% to 124.0 million euros and sales of Bemiparin increased 9% to 110.7 million euros.
  • EBITDA increased by 115% to 202.9 million euros.
  • Net profit increased by 151% to 153.1 million euros.
  • ROVI and Moderna announced a long-term collaboration to increase capacities for the compounding, aseptic filling, inspection, labeling, and packaging of ROVI’s facilities located in Madrid, San Sebastián de los Reyes and Alcalá de Henares. This new agreement, which has a term of ten years, includes a series of investments expected to allow the manufacturing capacity to increase across ROVI’s facilities in Madrid, Spain.
  • The European Commission has authorized the marketing of Okedi® (Risperidone ISM®) for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.
  • ROVI will propose to the Shareholders General Meeting a dividend of 0.9556 euros per share with dividend rights on 2021 earnings. This proposed dividend would mean an increase of 151% compared to the dividend on 2020 earnings (€0.3812/share) and represents a 35% pay-out.

 

OUTLOOK

For 2022, ROVI is upgrading its operating revenue guidance from a mid-single-digit growth rate to the range between 15% and 20%, compared to the forecast provided to the market in November 2021.

 

END OF THE SHARE BUY-BACK PROGRAMME

On 22 February 2022, ROVI informed that the Board of Directors resolved to finalize the share buy-back programme launched by the Company as of 3 November 2021, having acquired 1,492,108 own shares, this is, 89% of the maximum number of shares to be acquired under the buy-back programme.

 

LAUNCHING OF A NEW SHARE BUY-BACK PROGRAMME

On 22 February 2022, ROVI informed the market that, effective as of today's date, 23 February, 2022, a new share buy-back programme (the “Buy-back Program”) will commence under the following terms (see further information on pages 24-25):

  • Purpose and scope: the Buy-back Programme’s purpose is to redeem own shares of ROVI (share capital reduction) while, at the same time, increasing the remuneration of ROVI’s shareholders by raising earnings per share.
  • Term: from today, 23 February 2022, for a six-month period.
  • Maximum monetary amount: up to 46,000,000 euros.
  • Maximum number of shares to be acquired: 560,700 shares of the Company, representing approximately 1% of the Company’s share capital.
Average: 1 (1 vote)
 
Related
ROVI REPORTS OPERATING REVENUE GROWTH OF 57% AND NET PROFIT GROWTH OF 123% • Operating revenue increased by 57% to 205.6 million euros...
2 min
11/05/2022
Madrid – 08 April, 2022 - Moderna and ROVI Pharma Industrial Services, S.A.U. today announced a recall of one lot (lot #000190A) of the...
2 min
08/04/2022
Madrid, 4 de marzo de 2022 - Laboratorios Farmacéuticos Rovi, S.A. was certified carbon neutral in 2021 for the second year running....
3 min
04/03/2022